India Pain Management Drugs Market Size, Share, Opportunities, And Trends By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Acetaminophen, Opioid (Strong Opioid, Weak Opioid), Antidepressants, Anticonvulsant Drugs, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Indication (Cancer, Rheumatoid Arthritis, Chronic Back Pain, Post-Operative Pain, Others), And By State - Forecasts From 2025 To 2030

India Pain Management Drugs Market Size:

India pain management drugs market is anticipated to grow at a CAGR of 7.25% from 2025 to 2030.

India is one of the major APAC economies with high growth potential in the healthcare sector and the country is also witnessing a steady growth in out-of-pocket expenditure continues to be a major factor shaping the market growth in this country. Likewise, the growing diabetic population in India and increasing obesity among people are pushing up the number of people living with joint pain, thus increasing the demand for pain management drugs. According to the International Diabetes Federation, in 2024, the prevalence rate of diabetes was 10.5% among adults with 89,826,900 total number of cases being recorded.

Furthermore, this country has been witnessing a high incidence of cancer among people of all age groups which is expected to propel demand for pain management drugs. As per the Indian Council of Medical Research, in 2022, the projected number of new cancer cases in the country stood at 1,461,427 and is expected to show constant growth in the coming years. Besides growing chronic diseases, India also holds a high prevalence rate in arthritis and with the country’s growing old-age population the usage of pain management drugs for lower back and joint pain is also anticipated to show progression as such age group is more prone to varied body pain. 

According to Niti Ayog’s “Senior Care Reforms in India 2024” report, the elderly population strength is 104 million which accounts for 10% of the country’s total population and is projected to grow up to 19.5% by 2050. The phenomenal aging will impact the health aspects of society thereby creating more dependency on medication for overall health improvement.

Moreover, pain management drugs also play an integral role in post-surgical treatment for minimizing pain and improving recovery. For the past couple of years, the scale of surgical procedures in India has shown progression fuelled by the growing disease prevalence, accidental cases, and emphasis on aesthetic appeal. For instance, as per the International Society of Plastic Surgeons, in 2023, total surgical procedures stood at 531,792 which witnessed a significant 37.1% growth over the number of surgeries conducted in 2022.

Hence, due to these health factors and surgical procedures generic medicines are gaining traction in India. Growing awareness among people regarding the efficacy and safety of generic drugs is increasing their adoption among people, thus positively impacting the revenue of market players to an extent.

India Pain Management Drug Market Segmentation

• By Drug Type
  • Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Acetaminophen
  • Opioid
    • Strong Opioid
    • Weak Opioid
    • Antidepressants
  • Anticonvulsant Drugs
  • Others
• By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Indication
  • Cancer
  • Rheumatoid Arthritis
  • Chronic Back Pain
  • Post-Operative Pain
  • Others
• By State
  • Uttar Pradesh
  • Maharashtra
  • Madhya Pradesh
  • West Bengal
  • Rajasthan
  • Others

1. EXECUTIVE SUMMARY 

2. MARKET SNAPSHOT

2.1. Market Overview

2.2. Market Definition

2.3. Scope of the Study

2.4. Market Segmentation

3. BUSINESS LANDSCAPE 

3.1. Market Drivers

3.2. Market Restraints

3.3. Market Opportunities 

3.4. Porter’s Five Forces Analysis

3.5. Industry Value Chain Analysis

3.6. Policies and Regulations 

3.7. Strategic Recommendations 

4. TECHNOLOGICAL OUTLOOK

5. INDIA PAIN MANAGEMENT DRUGS MARKET BY DRUG TYPE

5.1. Introduction

5.2. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

5.3. Corticosteroids

5.4. Acetaminophen

5.5. Opioid

5.5.1. Strong Opioid

5.5.2. Weak Opioid

5.6. Antidepressants

5.7. Anticonvulsant Drugs

5.8. Others

6. INDIA PAIN MANAGEMENT DRUGS MARKET BY DISTRIBUTION CHANNEL

6.1. Introduction

6.2. Hospital Pharmacies

6.3. Retail Pharmacies 

6.4. Online Pharmacies

7. INDIA PAIN MANAGEMENT DRUGS MARKET BY INDICATION

7.1. Introduction

7.2. Cancer

7.3. Rheumatoid Arthritis

7.4. Chronic Back Pain

7.5. Post-Operative Pain

7.6. Others

8. INDIA PAIN MANAGEMENT DRUGS MARKET BY STATE

8.1. Introduction

8.2. Uttar Pradesh

8.2.1. By Drug Type

8.2.2. By Distribution Channel

8.2.3. By Indication

8.3. Maharashtra

8.3.1. By Drug Type

8.3.2. By Distribution Channel

8.3.3. By Indication

8.4. Madhya Pradesh

8.4.1. By Drug Type

8.4.2. By Distribution Channel

8.4.3. By Indication

8.5. West Bengal

8.5.1. By Drug Type

8.5.2. By Distribution Channel

8.5.3. By Indication

8.6. Rajasthan

8.6.1. By Drug Type

8.6.2. By Distribution Channel

8.6.3. By Indication

8.7. Others

8.7.1. By Drug Type

8.7.2. By Distribution Channel

8.7.3. By Indication

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

9.1. Major Players and Strategy Analysis

9.2. Market Share Analysis

9.3. Mergers, Acquisitions, Agreements, and Collaborations

9.4. Competitive Dashboard

10. COMPANY PROFILES

10.1. Novartis Pharmaceuticals Corporation (Novartis AG)

10.2. Eli Lilly and Company

10.3. Pfizer Inc.

10.4. GlaxoSmithKline plc

10.5. Sanofi S.A

10.6. Viatris Inc.

10.7. Abbott Laboratories

10.8. Anglo-French Drugs & Industries Ltd.

10.9. Rusan Pharma

10.10. Cipla

11. APPENDIX

11.1. Currency 

11.2. Assumptions

11.3. Base and Forecast Years Timeline

11.4. Key benefits for the stakeholders

11.5. Research Methodology 

11.6. Abbreviations 

Novartis Pharmaceuticals Corporation (Novartis AG)

Eli Lilly and Company

Pfizer Inc.

GlaxoSmithKline plc

Sanofi S.A

Viatris Inc.

Abbott Laboratories

Anglo-French Drugs & Industries Ltd.

Rusan Pharma

Cipla